Cargando…
Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca
BACKGROUND: Variant transthyretin amyloidosis (A-ATTRv) is an autosomal dominant disease caused by a range of TTR gene variants which entail great phenotypical heterogeneity and penetrance. In Majorca, the A-ATTRv caused by the V30M gene variant (A-ATTRV30M) is the most common. Since asymptomatic ca...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472571/ https://www.ncbi.nlm.nih.gov/pubmed/37653545 http://dx.doi.org/10.1186/s13023-023-02865-5 |
_version_ | 1785100105767976960 |
---|---|
author | Cisneros-Barroso, E. Gorram, F. Ribot-Sansó, M. A. Alarcon, F. Nuel, G. González-Moreno, J. Rodríguez, A. Hernandez-Rodriguez, J. Amengual-Cladera, E. Martínez-López, I. Ripoll-Vera, T. Losada-López, I. Heine-Suñer, D. Plante-Bordeneuve, V. |
author_facet | Cisneros-Barroso, E. Gorram, F. Ribot-Sansó, M. A. Alarcon, F. Nuel, G. González-Moreno, J. Rodríguez, A. Hernandez-Rodriguez, J. Amengual-Cladera, E. Martínez-López, I. Ripoll-Vera, T. Losada-López, I. Heine-Suñer, D. Plante-Bordeneuve, V. |
author_sort | Cisneros-Barroso, E. |
collection | PubMed |
description | BACKGROUND: Variant transthyretin amyloidosis (A-ATTRv) is an autosomal dominant disease caused by a range of TTR gene variants which entail great phenotypical heterogeneity and penetrance. In Majorca, the A-ATTRv caused by the V30M gene variant (A-ATTRV30M) is the most common. Since asymptomatic carriers are at risk of developing the disease, estimating age of onset is vital for proper management and follow-up. Thus, the aim of this study was to estimate age-related penetrance in ATTRV30M variant carriers from Majorca. METHODS: The disease risk among carriers from ATTRV30M families from Majorca was estimated by Non-parametric survival estimation. Factors potentially involved in the disease expression, namely gender and parent of origin were also analysed. RESULTS: A total of 48 heterozygous ATTRV30M families (147 affected patients and 123 were asymptomatic carriers) were included in the analysis. Penetrance progressively increased from 6% at 30 years to 75% at 90 years of age. In contrast to other European populations, we observe a similar risk for both males and females, and no difference of risk according to the parent of origin. CONCLUSIONS: In this first study assessing the age-related penetrance of ATTRV30M variant in Majorcan families, no effect of gender or parent of origin was observed. These findings will be helpful for improving management and follow-up of TTR variant carrier individuals. |
format | Online Article Text |
id | pubmed-10472571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104725712023-09-02 Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca Cisneros-Barroso, E. Gorram, F. Ribot-Sansó, M. A. Alarcon, F. Nuel, G. González-Moreno, J. Rodríguez, A. Hernandez-Rodriguez, J. Amengual-Cladera, E. Martínez-López, I. Ripoll-Vera, T. Losada-López, I. Heine-Suñer, D. Plante-Bordeneuve, V. Orphanet J Rare Dis Research BACKGROUND: Variant transthyretin amyloidosis (A-ATTRv) is an autosomal dominant disease caused by a range of TTR gene variants which entail great phenotypical heterogeneity and penetrance. In Majorca, the A-ATTRv caused by the V30M gene variant (A-ATTRV30M) is the most common. Since asymptomatic carriers are at risk of developing the disease, estimating age of onset is vital for proper management and follow-up. Thus, the aim of this study was to estimate age-related penetrance in ATTRV30M variant carriers from Majorca. METHODS: The disease risk among carriers from ATTRV30M families from Majorca was estimated by Non-parametric survival estimation. Factors potentially involved in the disease expression, namely gender and parent of origin were also analysed. RESULTS: A total of 48 heterozygous ATTRV30M families (147 affected patients and 123 were asymptomatic carriers) were included in the analysis. Penetrance progressively increased from 6% at 30 years to 75% at 90 years of age. In contrast to other European populations, we observe a similar risk for both males and females, and no difference of risk according to the parent of origin. CONCLUSIONS: In this first study assessing the age-related penetrance of ATTRV30M variant in Majorcan families, no effect of gender or parent of origin was observed. These findings will be helpful for improving management and follow-up of TTR variant carrier individuals. BioMed Central 2023-08-31 /pmc/articles/PMC10472571/ /pubmed/37653545 http://dx.doi.org/10.1186/s13023-023-02865-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cisneros-Barroso, E. Gorram, F. Ribot-Sansó, M. A. Alarcon, F. Nuel, G. González-Moreno, J. Rodríguez, A. Hernandez-Rodriguez, J. Amengual-Cladera, E. Martínez-López, I. Ripoll-Vera, T. Losada-López, I. Heine-Suñer, D. Plante-Bordeneuve, V. Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title | Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title_full | Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title_fullStr | Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title_full_unstemmed | Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title_short | Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca |
title_sort | disease risk estimates in v30m variant transthyretin amyloidosis (a-attrv) from mallorca |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472571/ https://www.ncbi.nlm.nih.gov/pubmed/37653545 http://dx.doi.org/10.1186/s13023-023-02865-5 |
work_keys_str_mv | AT cisnerosbarrosoe diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT gorramf diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT ribotsansoma diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT alarconf diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT nuelg diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT gonzalezmorenoj diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT rodrigueza diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT hernandezrodriguezj diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT amengualcladerae diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT martinezlopezi diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT ripollverat diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT losadalopezi diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT heinesunerd diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca AT plantebordeneuvev diseaseriskestimatesinv30mvarianttransthyretinamyloidosisaattrvfrommallorca |